April 02, 2010
– Comments (78)
continuation of this post.
cancel the open order (see comment #56 here).
Four Best Values in Biotech
STOCK SELECTION WILL BE the key to outperformance, in our opinion, because the valuation of the biotechnology sector, across the board, is currently neither compelling nor expensive. We favor stocks with cheaper valuations and strong pipelines. Among our Buy-rated stocks, we think the best four stocks to buy now are Amgen (ticker: AMGN), Spectrum Pharmaceuticals (SPPI), Isis Pharmaceuticals (ISIS) and Genzyme (GENZ).
We are adding Genzyme to our trading list, while Amgen, Isis and Spectrum remain on the list.
Russia Stocks Defy Terrorist Bombs as RTS Leads World
April 1 (Bloomberg) -- The deadliest terrorist attacks on Moscow since 2004 can’t stop Russian stocks from climbing more than every market worldwide this week.
The RTS Index jumped 5.8 percent since March 26, the steepest gain among 93 benchmark equity indexes tracked by Bloomberg, as an economic recovery in the world’s largest energy exporter leads East Capital and F&C Asset Management to say shares are attractive. The ruble strengthened 1 percent against the dollar, while the cost to protect against a government debt default declined.
Suicide bomber attacks on the Moscow subway three days ago and two blasts in Russia’s southern Dagestan region yesterday killed at least 51 people and injured more than 100. The attacks won’t curb Russia’s economic expansion as oil, the country’s main export, trades 75 percent higher than a year ago, according to East Capital and F&C. The RTS index is valued at 8.5 times analysts’ 2010 profit estimates, the lowest among 22 emerging- market countries, according to data compiled by Bloomberg.
“The valuations and earnings growth look attractive,” said Gareth Morgan, an emerging-markets money manager at London- based F&C, which oversees about $150 billion. On the bombings, “the markets tend to shrug them off, however regrettable,” he said.
ISIS (also see the articles and post linked to comment #24 here) and RSX are large positions in the "fund" currently.
RTS Index USD (Russia).
Jakarta Composite Index (Indonesia).
Jakarta Composite Index (Indonesia).
one of the next buys might be Talecris (TLCR).
buy 4200 RIGL limit 8.50 USD.
02/16/10 AstraZeneca and Rigel Pharmaceuticals Sign Worldwide License Agreement for Late-Stage Development Product -- Fostamatinib Disodium (R788) -- for the Treatment of Rheumatoid Arthritis (RA)
03/25/10 Investor Day presentation
Thanks for the information as always.
Well, I am not a chartist, but I think they usually like charts likes these ...
Qiagen (QGEN) in Frankfurt trading (chart "goes back further")
and Xetra trading.
consensus estimates for Qiagen.
rev. 2010: 856.23 million EUR,rev. 2011: 960.63 million EUR,
eps 2010: 0.69 EUR, eps 2011: 0.80 EUR,
"net cash" (year end (?)) 2010: 49.63 million EUR,"net cash" 2011: 229.37 million EUR.
market capitalisation: around 3.97 billion EUR.
market capitalisation of Aixtron (AIXG): around 2.75 billion EUR.
Qiagen and Aixtron (AIXG) have a decent chance of becoming components of the DAX30 index in the not so distant future ...
(from here: 12/31/09 Freefloat Ranking Share Indices (*.xls))
The leading index of Deutsche Börse AG comprises the 30 largest and most actively traded German equities (blue chips). The DAX stocks are admitted to either the Official Market or Regulated Market and are listed in Prime Standard. The criteria for weighting the stocks in the index are: trading volume and market capitalization on the basis of the number of shares in free float, as well as their respective sector. Deutsche Börse calculates DAX by the second on the basis of Xetra® prices. It decides whether changes are to be made to the composition of the index on an annual basis in September. Outside the regular review dates, a company can be taken out of the index if it does no longer belong to the 45 largest companies in terms of market capitalization and trading volume. Respectively, a company can be included in the index if it ranks among the 25 largest companies in terms of market capitalization and trading volume. The changeover takes effect as of the next scheduled chaining date.
They are currently among the "heavyweights" of the TecDax.
buy 770 EWP (all orders are to be executed on the "appropriate" U.S. exchange during regular trading hours unless I specify a different exchange or extended trading).
okay, this might have to do with my "home bias" as Spain is the country I spend most of my non-Germany hours in. REP and STD are already positions in the fund.
buy 1100 TKC limit 16.50 USD.
I just checked whether IBN, PTI or TKC are trading at a considerable discount in Indian or Turkish trading. They are not. If I were a less virtual fund manager I would have a less virtual secretary that would check that for me. And answer the phone ...
Hey Port!!! miss you, and I am needing my fix of the little green line chart :)
sell 2200 CRME limit 7.68.
bought 4200 RIGL 8.10 USD,bought 770 EWP 43.31 USD,bought 1100 TKC 15.54 USD,sold 2200 CRME 7.68 USD.
the little green line chart
updates are here.
sell 800 ATPG market (bid at $19.18).
okay, I missed the end of trading, so just forget about comment #17, hehe ...
Have you taken a look at HNR at all??
buy 230 TLCR, limit $21.
buy 450 NKTR, limit $16.50.
buy 200 YPF, limit $44.50.
buy 390 ECH, limit $58.00,
buy 320 EPU, limit $36.00.
EMC's Storage Networking Business Poised for Recovery
EMC: Piper Ups Rating To Overweight On Valuation Basis
you dont like CRME anymore at this price? You dont see any more upside for folks who have been holding on to it and enjoying the gains?
and all this sells/buys in your posts above - are they real transactions on your part? thanks
you dont like CRME anymore at this price?
these are the CRME "transactions".
bought 9000 shares at $5.49 on 03/08/10.bought 7000 shares at $6.57 on 03/12/10.sold 7000 shares at $6.57 on 03/22/10.sold 2200 shares at $7.68 on 04/05/10.
CRME is still one of the largest positions. I might sell a few more shares in a few weeks if it "keeps rising" ...
You dont see any more upside for folks who have been holding on to it and enjoying the gains?
I think it is reasonable to expect some more "upside", but depending on the size of your position in relation to your entire portfolio you might want to sell a few shares. CRME is still one of my favourite stocks (see here).
A post suggesting some "profit taking" written on 01/13/10 is here.
and all this sells/buys in your posts above - are they real transactions on your part?
No, they are virtual transactions. I post the trades I would make if I were a fund manager (of a more or less regular equity fund, allowed to use some short selling and buying on margin). I post the orders and the price an intelligent trader would have been able to get for the "executed" orders.
wow - real time response...haha
thanks Port....really appreciate it...
check out my post in your NBI post...about tech and chinese tech etfs...Thanks
sell 13000 LXRX, limit $1.48.buy 1250 EWM, $12.40.
bought 230 TLCR 19.74 USD,bought 450 NKTR 15.52 USD,bought 390 ECH 56.19 USD,bought 320 EPU 34.60 USD,bought 1250 EWM 12.00 USD,sold 13000 LXRX 1.59 USD.
YPF order is still open.
sell 2100 ANDS 2.67 USD.
bought 200 YPF 44.50 USD.sold 2100 ANDS 2.67 USD.
sell 340 TRGT, limit $21.63.
sold 340 TRGT 21.63 USD.
buy 6000 RXII 4.22 USD.
bought 6000 RXII 4.205 USD.
F5, Radware Shares Surge As Neglected Niche Booms
The "fund" currently has an FFIV and an RDWR position.
#292) On March 23, 2009 at 7:52 AM, portefeuille (99.97) wrote: FFIV - 20.61 - outperform
#293) On March 23, 2009 at 7:57 AM, portefeuille (99.97) wrote: RDWR - 5.40 - outperform
#573) On July 13, 2009 at 8:12 AM, portefeuille (99.97) wrote: FFIV - end outperform - 33.52 - no new rating
#997) On February 12, 2010 at 8:53 PM, portefeuille (99.97) wrote: FFIV - 55.35 - outperform
buy (to cover) 2000 HUSA, limit 16.42 USD.
bought 2000 HUSA 16.25 USD.
buy (to cover) 400 HUSA, limit 15.70 USD.
sell 1330 ATPG, limit 19.19 USD.
sold 1330 ATPG 19.21 USD.
sell 1500 PALM, limit 4.39 USD.
sold 1500 PALM 4.41 USD.
sell 1000 PALM 4.72 USD.
bought 400 HUSA 15.70 USD.
sold 1000 PALM 4.72 USD.
sell SA, limit 27.29 USD.
sell 350 SA, limit 27.29 USD.
sold 350 SA 27.33 USD.
buy 4400 MRNA, limit 1.30 USD.
buy 370 FRX, limit 29.90 USD.
buy 1200 OTE, limit 7.10 USD.
Hellenic Telecommunications Organization (Οργανισμός Τηλεπικοινωνιών Ελλάδος, hehe ...) in Berlin trading.
buy 900 ALPHA:GA, limit 6.30 EUR.
Alpha Bank in Frankfurt trading.
bought 900 ALPHA:GA 6.19 EUR.
buy 850 ETE:GA, limit 13.30 EUR.
National Bank of Greece in Frankfurt trading.
850 ETE:GA are "equivalent" to 850 * 5 = 4250 NBG shares (ADR ratio is 5:1).
bought 4250 NBG 3.4459 USD (12.94 EUR * 1.3315 USD/EUR / 5).
The 900 ALPHA:GA shares were bought for 8.24 USD per share (6.19 EUR * 1.3315 USD/EUR, see comment #60 above).
buy 370 FRX, limit 29.40 USD in pre-market trading.
bought 370 FRX 29.09 USD.
buy 6500 UCG:IM, limit 2.20 EUR.
bought 6500 UCG:IM 2.9011 USD (2.18 EUR),bought 4400 MRNA 1.22 USD,bought 1200 OTE 5.87 USD.
sell 5500 YMI, limit 1.42 USD.
sold 5500 YMI 1.42 USD.
sell 2700 EXAS, limit 4.85 USD.
sell 550 AMLN, limit 23.50 USD,sell 3100 ARIA, limit 3.41 USD.
sold 550 AMLN 23.50 USD.
sell 250 SA, limit 28.25 USD.
buy 1200 ORX:SS, limit 44.00 SEK.
sell 780 INCY, limit 14.56 USD.
sold 780 INCY 14.56 USD,sold 3100 ARIA 3.41 USD.
sold 250 SA 28.25 USD.
sell 6000 ARYX, limit 0.99 USD.
sold 6000 ARYX 0.99 USD.